PHARMACOLOGY AND THERAPEUTIC RADIOPHARMACEUTICALS
(SESSION 8)
Biological and chemical evaluation of various radiocolloids
used for clinical radiosynovectomy .............................. 3
G.A. Jánoki, L. Balogh, A. Polyák, D. Máthé, K. Korösi,
R. Király
Targeted radiotherapy with alpha particle emitting
radionuclides .................................................. 25
M.R. Zalutsky, O.R. Pozzi, G. Vaidyanathan
DOTA-Tyr3-octreotate labelled with 177Lu and 131I .............. 39
V. Lungu, D. Niculae, D. Chiper, M. Radu
177Lu labelled nitroimadzoles and nitrotriazoles for
possible use in targetedtherapy of hypoxic tumours ............. 51
T. Das, S. Chakraborty, A. Mukherjee, S. Banerjee, G.
Samuel, H.D. Sarma, M. Venkatesh
Labelling and biological evaluation of anti-CD20 for
treatment of non-Hodgkin's lymphoma ............................ 63
P. Oliver, A. Robles, V. Trindade, P. Cabral, V.
Tortarolo, A. Nappa, G. Rodriguez, H. Baiter
THERAPEUTIC RADIOPHARMACEUTICALS
(SESSION 9)
177Lu-DOTA-J591 monoclonal antibody: Chemistry, toxicity,
dosimetry and clinical efficacy ................................ 73
S.J. Goldsmith, S. Vallabhajosula, M.I. Milowsky, D.M.
Nanus, N.H. Bander
Radiolabeled somatostatin analogues for radionuclide therapy
of tumours ..................................................... 91
M. de Jong, D. Kwekkeboom, R. Valkema, E. Krenning
Iodine whole body scan, thyroglobulin levels, 99mTc MIBI
scan and computed tomography .................................. 109
N.Ö. Kücük, S.S. Gültekin, G. Aras, E. Ibis
99mTc-MIBl and l34I scintigraphy in the follow-up of
differentiated thyroid carcinoma (DTC) patients after
surgery ....................................................... 123
S. Sergieva, T. Hadjieva, V. Botev, A. Dudov
Results of knee radiosynoviortesis in haemophilic and
rheumatoid arthritic patients with 32P colloid of local
production .................................................... 135
V.E. Soroa, M.H. Velázquez Espeche, C. Giannone,
G. Naswetter, H. Caviglia, G. Galatros
PET RADIOPHARMACEUTICALS
(SESSION 10)
Alternative methods of making [11C]amides: Application to
the preparation of 5-HTIA receptor radioligands ............... 147
V.W. Pike, S.Y. Lu, J. Hong, J.L. Musachio,
J. A. McCarron
[18F]fluoroethylated and [11C]methylated PET tracers for
research and routine diagnosis ................................ 161
M. Mitterhauser, W. Wadsak
A novel finding: Anti-androgen flutamide kills androgen
independent PC-3 cells ........................................ 183
F. Al-Saeedi
A semi-automated [l3N]NH3 production module: Design,
quality control and optimization .............................. 195
A.R. Jalilian, P. Rowshanfarzad, M. Sabet, M. Mirzaii,
A. Ziaee, D. Sardari
RADIOIODINE RADIOPHARMACEUTICALS
(SESSION 11)
Production of radioiodines with medical PET cyclotrons ........ 209
J.J. Comor, G.-J. Beyer, G. Pimentel-Gonzales
New developments in radioiodinated radiopharmaceuticals for
SPECT and radionuclide therapy: [123I]/[I31I] labelled L-
and D-phenylalanine analogues ................................. 223
M. Bauwens, J.J.R. Mertens, T. Lahoutte, K. Kersemans,
C. Gallez, A. Bossuyt
Comparison of 131I-TYR3-octreotate and 131I-DOTA-TYR3-
octreotate: The effect of DOTA on pharmacokinetics and
stability ..................................................... 243
E.B. de Araújo, E. Muramoto, L.T. Nagamati, J.S. Caldelra
Filho, R.M. Couto, C.P.G. Silva
Iodine labelled diethylstilbestrol (DES) of high specific
activity: A potential radiopharmaceutical for therapy of
estrogen receptor positive tumours and their metastases? ...... 253
T. Fischer, H. Schicha, K. Schomácker
18F RADIOPHARMACEUTICALS AND AUTOMATION OF SYNTHESIS
(SESSION 12)
18F based radiopharmaceuticals and automation of synthesis .... 265
P.K. Garg, S. Garg
Rapid method for radiofluorination of pyridine derivatives:
Prosthetic groups for labelling bioactive molecules ........... 283
I. Al Jammaz, B. Al Otaibi, H. Ravert, J. Amartey
l-[l8F]fluoroethyleneglycol-2-nitroimidazoles: A novel
class of potential hypoxia PET markers ........................ 295
R.J. Abdel-Jalil, M. Übele, W. Ehrlichmann, W. Voelter,
H.-J. Machulla
Radiosynthesis and in vivo evaluation in melanoma-bearing
mice of 0-(2-[18F]fluoroethyl)-L-tyrosine as a tumour
tracer ........................................................ 297
Mingwei Wang, Duanzhi Yin, Yongxian Wang
CYCLOTRON BASED RADIONUCLIDES AND GENERATORS
(SESSION 13)
Production of radionuclides with a cyclotron .................. 311
D.J. Schlyer
Perspectives for the large scale production of
radiolanthanides with medical potential ....................... 331
G.-J. Beyer, H.L. Ravn, U. Köster
Production of 123I-MIBG IPEN-CNEN/SP .......................... 349
M.F. de Barboza, V. Sciani, R. Herrerias, M.M.N. Matsuda,
N.T.O. Fukumori, L.C.A. Sumiya, H. Matsuda, A.A. Souza,
M.M. Goes, J.T. Pires, J. Mengatti, C.P. Gomez da Silva
A new 82Sr-82Rb generator ..................................... 353
A. Bilewicz, B. Bartos, R. Misiak, B. Petelenz
Cyclotron production of 103Pd via proton induced reactions
on a 103Rh target ............................................. 357
M. Sadeghi, H. Afarideh, G. Raisali, M. Haji-Saeid
The status and potential of new radionuclide generators
providing positron emitters to synthesize new targeting
vectors for PET ............................................... 367
F. Roesch, K.P. Zhernosekov, D.V. Filosofov, M. Jahn,
M. Jennewein
RADIOPHARMACY
(SESSION 14)
Nuclear pharmacy practices in the United States of America .... 385
K. Ozker
Regulatory aspects of hospital radiopharmacy and clinical
trials ........................................................ 391
A.A. Soylu
Standardization and quality control of an in-house
formulation of 99mTc(V)-DMSA in tumour imaging and
assessment of tumour biology: Work in progress ................ 399
P.S. Choudhury, N.C. Goomer, A. Gupta, D.C. Doval, T.
Kataria, A.K. Vaid, P.K. Sharma
Development of centralized radiopharmacies in Spain:
A successful experience in Europe ............................. 413
I. Oyarzábal, R. Jiménez-Shaw
Chairpersons of Sessions ...................................... 421
Secretariat of the Symposium .................................. 422
Programme Committee ........................................... 422
List of Participants .......................................... 423
Author Index .................................................. 461
|
